The explanations are: (1) during treatment, the inflammation of RA is attenuated, then MALT1 closely relates to RA inflammation, so MALT1 is decreased together with inflammation (12, 14, 20); (2) bDMARDs or csDMARDs treatment may regulate multiple immune cells to affect MALT1 level in patients (29, 30). The gene discussed is MALT1; the disease is rheumatoid arthritis.